Jiskyn

Bendamustine Hydrochloride, the active ingredient in Jiskyn, is an alkylating agent presented as a sterile solution for injection for intravenous use. It is employed in the treatment of chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients, targeting malignant lymphoid cells.

GNH USA supplies Jiskyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this chemotherapy agent for qualified healthcare providers. The company adheres to stringent quality standards and offers comprehensive logistical support for global distribution.

Bendamustine Hydrochloride is an alkylating chemotherapy used in hematologic malignancies.

- Chronic lymphocytic leukemia (CLL): improves remission rates and disease control in adult patients. - Non‑Hodgkin lymphoma (NHL): induces tumor regression and prolongs progression‑free survival in eligible individuals. - Relapsed or refractory lymphoid malignancies: offers an additional treatment line for patients whose disease has progressed after prior therapy.

Bendamustine Hydrochloride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Fatigue: generalized tiredness. - Thrombocytopenia: reduced platelet count. - Neutropenia: lowered neutrophil levels. - Fever: low‑grade temperature elevation.

Serious or Rare Side Effects: - Severe infections: due to profound immunosuppression. - Secondary malignancies: rare development of new cancers. - Cardiotoxicity: uncommon impairment of heart function.

When using Jiskyn, careful monitoring and precautionary measures are essential.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess infection risk: watch for signs of febrile neutropenia. - Evaluate liver function: adjust therapy if hepatic impairment is present. - Use contraception: avoid pregnancy because safety is unknown. - Discontinue on hypersensitivity: stop treatment if allergic reaction occurs. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine Hydrochloride can interact with several drug classes; awareness helps manage safety.

Major Interactions (Avoid): - Concurrent alkylating agents: may amplify myelosuppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase bendamustine exposure. - Live vaccines: heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk when thrombocytopenia occurs. - Granulocyte‑colony stimulating factors: may alter blood‑count recovery dynamics. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic efficacy.